Itch is defined as an irritating sensation that triggers a desire to scratch. The signaling pathways of itch fall into two main categories, histaminergic and non-histaminergic pathway. Mainly, C fibers transmit itch information in both pathways. Since it is known that α₂δ subunits composing voltage-gated Ca²⁺ channels are expressed in C fibers, mirogabalin, a novel gabapentinoid that targets these subunits, may be applicable as an antipruritic drug. In this study, using male ICR mice, we showed effect of mirogabalin on scratching behavior induced by several pruritogens (histamine, chloroquine and compound 48/80). Scratching bouts increased by these pruritogens are decreased by oral administration of mirogabalin (10 mg/kg). The oral administration of mirogabalin (10 mg/kg) exhibited no sedation. In addition, the scratch behavior was inhibited by intracisternal injection of mirogabalin, but not local intradermal injection. These results suggest that mirogabalin is effective against itch transmitted through both histaminergic and non-histaminergic pathway and also that central nerve system, especially spinal cord, are involved in the antipruritic effect of mirogabalin.